Zyvox® Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries

Diagnostic Microbiology and Infectious Disease

Volumn 59, Issue 2, 2007, Pages 199-209

  Jones, Ronald N ^a,b   Fritsche, Thomas R ^a   Sader, Helio S ^a,c   Ross, James E ^a  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Linezolid; MRSA; Oxazolidinone; Resistance; ZAAPS

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; METICILLIN; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; STREPTOMYCIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; ASIA; AUSTRALIA; BACTERIUM DETECTION; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; BRAZIL; CENTRAL AMERICA; CHINA; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG POTENCY; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; EUROPE; GERMANY; GRAM POSITIVE BACTERIUM; ITALY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MUTATION; NONHUMAN; PRIORITY JOURNAL; SOUTH AMERICA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; BACTERIAL INFECTION; DRUG EFFECT; GRAM POSITIVE COCCI; HEALTH; HEALTH SURVEY; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

ACETAMIDES; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HUMANS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; POPULATION SURVEILLANCE; WORLD HEALTH;

EID: 34748921084     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2007.06.001     Document Type: Article

References (56)

1. Anderegg T.R., Sader H.S., Fritsche T.R., Ross J.E., and Jones R.N. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. Int. J. Antimicrob. Agents. 26 (2005) 13-21
2. Antony S.J., Bitter K.M., Moreland T., Raudales F., and Diaz-Luna H. Methicillin-resistant Staphylococcus aureus infection in a renal allograft recipient treated successfully with a novel new antimicrobial agent (linezolid): new treatment options for infections due to resistant organisms. Clin. Infect. Dis. 29 (1999) 1341-1342
3. Babcock H.M., Ritchie D.J., Christiansen E., Starlin R., Little R., and Stanley S. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin. Infect. Dis. 32 (2001) 1373-1375
4. Ballow C.H., Biedenbach D.J., Rossi F., and Jones R.N. Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox(R) Antimicrobial Potency Study in Latin America (LA-ZAPS). Braz. J. Infect. Dis. 6 (2002) 100-109
5. Ballow C.H., Jones R.N., and Biedenbach D.J. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn. Microbiol. Infect. Dis. 43 (2002) 75-83
6. Bell J.M., Turnidge J.D., Ballow C.H., and Jones R.N. Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific. J. Antimicrob. Chemother. 51 (2003) 339-345
7. Biedenbach D.J., and Jones R.N. Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents. J. Clin. Microbiol. 35 (1997) 3198-3202
8. Birmingham M.C., Rayner C.R., Meagher A.K., Flavin S.M., Batts D.H., and Schentag J.J. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin. Infect. Dis. 36 (2003) 159-168
9. Bolmstrom A., Ballow C.H., Qwarnstrom A., Biedenbach D.J., and Jones R.N. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe). Clin. Microbiol. Infect. 8 (2002) 791-800
10. Brauers J., Kresken M., Hafner D., and Shah P.M. Surveillance of linezolid resistance in Germany, 2001-2002. Clin. Microbiol. Infect. 11 (2005) 39-46
11. Cercenado E., Garcia-Garrote F., and Bouza E. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates. J. Antimicrob. Chemother. 47 (2001) 77-81
12. Chen D.K., McGeer A., de Azavedo J.C., and Low D.E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N. Engl. J. Med. 341 (1999) 233-239
13. Chien J.W., Kucia M.L., and Salata R.A. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant Gram-positive bacterial infections. Clin. Infect. Dis. 30 (2000) 146-151
14. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard M7-A7. 7th ed. (2006), CLSI, Wayne, PA
15. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests: Approved Standard M2-A9. 9th ed. (2006), CLSI, Wayne, PA
16. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 17th Informational Supplement. M100-S17 (2007), CLSI, Wayne, PA
17. College of American Pathologists. Microbiology Surveys Program; Critique for D-05, S. aureus (2005), CAP, Chicago, IL
18. Diekema D.J., and Jones R.N. Oxazolidinone antibiotics. Lancet 358 (2001) 1975-1982
19. Draghi D.C., Sheehan D.J., Hogan P., and Sahm D.F. In vitro activity of linezolid against key gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program. Antimicrob. Agents Chemother. 49 (2005) 5024-5032
20. Draghi D.C., Sheehan D.J., Hogan P., and Sahm D.F. Current antimicrobial resistance profiles among methicillin-resistant Staphylococcus aureus encountered in the outpatient setting. Diagn. Microbiol. Infect. Dis. 55 (2006) 129-133
21. Farrell D.J., Morrissey I., Bakker S., Buckridge S., and Felmingham D. In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations. Antimicrob. Agents Chemother. 48 (2004) 3169-3171
22. Gales A.C., Sader H.S., Andrade S.S., Lutz L., Machado A., and Barth A.L. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int. J. Antimicrob. Agents. 27 (2006) 300-302
23. Gemmell C.G. Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison. J. Antimicrob. Chemother. 48 (2001) 47-52
24. Henwood C.J., Livermore D.M., Johnson A.P., James D., Warner M., and Gardiner A. Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group. J. Antimicrob. Chemother. 46 (2000) 931-940
25. Jones R.N., Ballow C.H., and Biedenbach D.J. Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States. Diagn. Microbiol. Infect. Dis. 40 (2001) 59-66
26. Jones R.N., Della-Latta P., Lee L.V., and Biedenbach D.J. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 42 (2002) 137-139
27. Jones R.N., Ross J.E., Fritsche T.R., and Sader H.S. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J. Antimicrob. Chemother. 57 (2006) 279-287
28. Kelly S., Collins J., Davin M., Gowing C., and Murphy P.G. Linezolid resistance in coagulase-negative staphylococci. J. Antimicrob. Chemother. 58 (2006) 898-899 (author reply 898-900)
29. Kollef M.H., Rello J., Cammarata S.K., Croos-Dabrera R.V., and Wunderink R.G. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med. 30 (2004) 388-394
30. Livermore D.M. Linezolid in vitro: mechanism and antibacterial spectrum. J. Antimicrob. Chemother. 51 Suppl 2 (2003) ii9-ii16
31. McNeil S.A., Clark N.M., Chandrasekar P.H., and Kauffman C.A. Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with Synercid (quinupristin/dalfopristin). Clin. Infect. Dis. 30 (2000) 403-404
32. Meka V.G., and Gold H.S. Antimicrobial resistance to linezolid. Clin. Infect. Dis. 39 (2004) 1010-1015
33. Melzer M., Goldsmith D., and Gransden W. Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving hemodialysis and with persistent methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus bacteremias. Clin. Infect. Dis. 31 (2000) 208-209
34. Moellering R.C. Linezolid: the first oxazolidinone antimicrobial. Ann. Intern. Med. 138 (2003) 135-142
35. Mutnick A.H., Biedenbach D.J., Turnidge J.D., and Jones R.N. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn. Microbiol. Infect. Dis. 43 (2002) 65-73
36. Mutnick A.H., Enne V., and Jones R.N. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. Ann. Pharmacother. 37 (2003) 769-774
37. Mylona E., Fanourgiakis P., Vryonis E., Golfinopoulou S., Skoutelis A., Platsouka E., and Chatzis N. Linezolid-based therapy in Staphylococcus epidermidis endocarditis. Int. J. Antimicrob. Agents 29 (2007) 597-598
38. Noskin G.A., Siddiqui F., Stosor V., Kruzynski J., and Peterson L.R. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin. Clin. Infect. Dis. 28 (1999) 689-690
39. Pai M.P., Rodvold K.A., Schreckenberger P.C., Gonzales R.D., Petrolatti J.M., and Quinn J.P. Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium. Clin. Infect. Dis. 35 (2002) 1269-1272
40. Poppe S., Schaadt R., Sheehan D., Sahm D., Zurenko G., and Shinabarger D. Mutation analysis of Staphylococcus aureus isolates demonstrating trailing linezolid (LZD) endpoints in microdilution MIC assays, Abstr A-088. American Society for Microbiology, 106th General Meeting Orlando (2006) 20
41. Potoski B.A., Adams J., Clarke L., Shutt K., Linden P.K., Baxter C., Pasculle A.W., Capitano B., Peleg A.Y., Szabo D., and Paterson D.L. Epidemiological profile of linezolid-resistant coagulase-negative staphylococci. Clin. Infect. Dis. 43 (2006) 165-171
42. Raad I.I., Hanna H.A., Hachem R.Y., Dvorak T., Arbuckle R.B., Chaiban G., and Rice L.B. Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin. Antimicrob. Agents Chemother. 48 (2004) 3583-3585
43. Rahim S., Pillai S.K., Gold H.S., Venkataraman L., Inglima K., and Press R.A. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin. Infect. Dis. 36 (2003) E146-E148
44. Ross J.E., Anderegg T.R., Sader H.S., Fritsche T.R., and Jones R.N. Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. Diagn. Microbiol. Infect. Dis. 52 (2005) 53-58
45. Ross J.E., Fritsche T.R., Sader H.S., and Jones R.N. Oxazolidinone susceptibility patterns for 2005: international report from the Zyvox® Annual Appraisal of Potency and Spectrum Study. Int. J. Antimicrob. Agents 29 (2007) 295-301
46. Rubinstein E., Cammarata S., Oliphant T., and Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin. Infect. Dis. 32 (2001) 402-412
47. Sahm D.F., Draghi D.C., Blosser R.S., Hogan P.A., and Sheehan D.J. Evaluation of broth microdilution (BMD) and Etest (E) for determining in vitro activity of linezolid (LZ) against S. aureus (SA) and enterococci (EN), Abstr C-320. American Society for Microbiology, 105th General Meeting (2005), Atlanta, GA 171
48. Shorr A.F., Kunkel M.J., and Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J. Antimicrob. Chemother. 56 (2005) 923-929
49. Stevens D.L., Herr D., Lampiris H., Hunt J.L., Batts D.H., and Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 34 (2002) 1481-1490
50. Stevens D.L., Smith L.G., Bruss J.B., McConnell-Martin M.A., Duvall S.E., Todd W.M., and Hafkin B. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 44 (2000) 3408-3413
51. Styers D., Sheehan D.J., Hogan P., and Sahm D.F. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann. Clin. Microbiol. Antimicrobial. 5 (2006) 2
52. Weigelt J., Itani K., Stevens D., Lau W., Dryden M., and Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 49 (2005) 2260-2266
53. Wunderink R.G., Cammarata S.K., Oliphant T.H., and Kollef M.H. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin. Ther. 25 (2003) 980-992
54. Wunderink R.G., Rello J., Cammarata S.K., Croos-Dabrera R.V., and Kollef M.H. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124 (2003) 1789-1797
55. Zeana C., Kubin C.J., Della-Latta P., and Hammer S.M. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Clin. Infect. Dis. 33 (2001) 477-482
56. Zyvox Package Insert. Pfizer. Available at (2004). http://www.pfizer.com/pfizer/download/uspi_zyvox.pdf